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Abstract Dietary supplementation of dried plum (DP)
prevents bone loss and restores bone mass in osteopenic
animal models. This study was designed to determine the
effects of DP supplementation on bone metabolic activity
over time using adult (6-month-old) male C57BL/6 mice
(n = 40) receiving control (CON = AIN93 M) or CON?
DP 25 % (w/w) diets for 4 or 12 weeks. After 4 weeks of
treatment, animals consuming the DP diet had a higher
whole-body bone mineral density, vertebral trabecular bone
volume (BV/TV), and femoral cortical thickness compared to
the CON animals. In the distal metaphysis of the femur, BV/
TV was increased in the DP-treated animals, but only after
12 weeks. Bone histomorphometric analyses revealed that
DP decreased osteoblast surface (67 %) and osteoclast sur-
face (62 %) at 4 weeks, but these surfaces normalized to the
CON animals by 12 weeks. Coincident with these changes,
the mineralizing surface (MS/BS) and cancellous bone for-
mation rate (BFR/BS) were reduced at 4 weeks in the DP
group compared to the CON, but by 12 weeks of DP sup-
plementation, BFR/BS (*twofold) and MS/BS (*1.7-fold)
tended to be increased (p \ 0.10). The relative abundance of
RNA for key regulators of osteoblast and osteoclast differ-
entiation and indicators of osteoblast activity were reduced in
the DP group at 4 weeks with no difference between groups at
12 weeks. These results indicate that supplementing the diet
with DP initially suppressed cancellous bone turnover, but a
biphasic response occurs over time, resulting in a positive
effect on bone mass and structure.
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Introduction
Age-related osteoporosis is a significant public health prob-
lem for both men and women. Projected estimates indicate
that by 2020, 50 % of women and 25 % of men over the age
of 50 years will experience an osteoporotic fracture during
their lifetime [1]. Fractures not only compromise activities of
daily living but also increase overall mortality, especially in
the 12 months immediately after a hip fracture [2]. The adult
skeleton undergoes bone remodeling, and optimal bone
health requires a metabolic balance between bone formation
by osteoblasts and bone resorption by osteoclasts. In age-
related bone loss, osteoclast and osteoblast activity becomes
uncoupled, resulting in a reduced rate of bone formation
relative to the rate of bone degradation [3]. This uncoupling
of bone cell activity has been attributed to multiple factors,
including increased prevalence of nutritional insufficiencies
(e.g., calcium, vitamin D, and protein), age-related altera-
tions in endocrine status (e.g., decreased estrogen and in-
sulinlike growth factor or IGF-1), decreased physical
activity, increased use of medications that affect bone, and
bone cell senescence [4, 5].
The authors report that they have no conflict of interest.
B. J. Smith (&)  J. L. Graef  ERendina 
K. A. Clark  S. L. Clarke  E. A. Lucas
Department of Nutritional Sciences, 420 College of Human
Sciences, Oklahoma State University, Stillwater, OK, USA
e-mail: bjsmith@okstate.edu
T. J. Wronski  A. A. Williams
Department of Physiological Sciences, College of Veterinary
Medicine, University of Florida, Gainesville, FL, USA
B. P. Halloran
Division of Endocrinology, Department of Medicine, Veterans
Affairs Medical Center, University of California at San
Francisco, San Francisco, CA, USA
123
Calcif Tissue Int (2014) 94:442–453
DOI 10.1007/s00223-013-9819-2
Current treatment strategies for osteoporosis consist of
several different options with antiresorptive and anabolic
properties [3]. The available antiresorptive therapies
include bisphosphonates, hormone replacement therapy,
denosumab, and selective estrogen receptor modulators,
with bisphosphonates being the most commonly prescribed
class of drugs [3]. Intermittent parathyroid hormone ther-
apy is the only U.S. Food and Drug Administration-
approved anabolic agent for treatment of patients with
severe osteoporosis [3, 6]. In many countries, strontium
ranelate is considered an attractive treatment option that
reputedly has both anabolic and antiresorptive properties,
but it has not received approval for use in the United States
[3, 7]. Despite these significant advances in pharmacolog-
ical options for the treatment of osteoporosis over the past
two decades, issues with patient compliance, adverse
effects, cost, and long-term efficacy have remained [3].
Another approach, nutritional supplementation, has typi-
cally focused on calcium and vitamin D. The combination
of calcium and vitamin D has been promoted for reducing
the risk of fracture primarily by reducing bone resorption.
However, recent recommendations by the U.S. Preventive
Services Task Force have brought the use of calcium and
vitamin D supplementation (B1,000 mg Ca2? and
B400 IU D3) as a primary fracture prevention strategy into
question [8]. Therefore, the search has continued for
effective, low-cost treatment strategies with fewer side
effects.
Among the dietary approaches that have been considered,
dried plum (DP) has demonstrated unique biological activity
that is based on its ability to prevent and reverse bone loss.
Studies in animal models of gonadal hormone deficiency
have provided important insight into this response [9–12].
For example, DP supplementation prevented bone loss
associated with ovarian hormone deficiency in C57BL/6
mice [12] and has been demonstrated to be more effective
than other fruits in its ability to restore bone in osteopenic
ovariectomized mice [11]. In male osteoporosis, DP sup-
plementation was shown to prevent orchidectomy-induced
bone loss by Sprague–Dawley rats [10], and in a subsequent
study, DP restored bone in this animal model [9]. Interest-
ingly, DPs capacity to restore trabecular bone in the oste-
openic animals was similar to intermittent parathyroid
hormone treatment [9]. Findings from these studies dem-
onstrated that DP suppressed bone resorption as indicated by
systemic markers of bone resorption (e.g., urinary deoxy-
pyridinoline excretion and serum pyridinoline crosslinks),
which was mediated by the down-regulation of osteo-
clastogenesis through the suppression of receptor activator
for NF-kappa B ligand (RANKL) signaling [9, 10]. In sev-
eral studies, the decrease in bone resorption coincided with
an increase in serum IGF-I, but the extent to which bone
formation is altered remains unclear [10, 13]. Clinical
studies have also supported the efficacy of DP supplemen-
tation on bone health [13, 14].
In addition to the effects of DP on bone in gonadal hor-
mone deficiency, it has also been shown to be effective in
improving bone parameters in age-related bone loss.
Recently we reported that male adult and old C57BL/6J
mice (i.e., 6 and 18 months of age) fed a DP-supplemented
diet for 6 months experienced a 48 and 34 % increase,
respectively, in trabecular bone volume in the distal femoral
metaphysis [15]. On the basis of in vivo microcomputed
tomography (microCT) data from that study, the majority of
the response to DP occurred during the first 3 months of the
study, but the mechanism by which DP exerted these ben-
eficial effects remained unclear. Until now, to our knowl-
edge, no studies have examined the effects of DP
supplementation on age-related bone loss at early time
points. This study was designed to gain a better under-
standing of the bone metabolic changes occurring in
response to DP supplementation during the first 12 weeks of
treatment and the mechanisms involved in a murine model
of age-related osteoporosis. The hypothesis to be tested was
that DP supplementation would increase indices of bone
formation and suppress resorption at 4 and 12 weeks, which
would result in improved bone structural properties.
Materials and Methods
Animal Care, Diet, and Necropsy
Six-month-old male C57BL/6 mice (n = 40; Charles River
Laboratories, Wilmington, MA, USA) were assigned to
AIN-93M control diet or control diet with 25 % (w/w) DP
for 4 or 12 weeks (n = 10/group). The DP powder was
provided by the California Dried Plum Board. The detailed
formulation of the DP diet has been published previously
[12]. The mice were allowed to acclimate to an environ-
mentally controlled room on a 12-h light/dark cycle in an
animal care facility for 3 days before beginning con-
sumption of the experimental diets. The mice were group
housed (4–5 mice/cage) on wire-bottom grids to minimize
coprophagic activity and had free access to deionized water
throughout the treatment period. Body weights and food
consumption were monitored weekly.
After the 4- or 12-week treatment period, the mice were
fasted for 6 h before anesthetization with a ketamine
(70 mg/kg body weight) and xylazine (3 mg/kg body
weight) mixture. Whole body dual-energy X-ray absorpti-
ometry scans (DXA; Lunar PIXImus, Madison, WI, USA)
were performed. The animals were then bled from the
carotid artery, and blood was collected and allowed to
coagulate for 15–20 min before separation of serum by
centrifugation (3,000 rpm 9 20 min). The serum was
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aliquoted and stored at -80 C until analyses were per-
formed. One femur from each animal was flushed with ice-
cold PBS, and RNA was extracted from the bone marrow
and hard tissue separately. The other femur was collected
and stored in PBF for 48 h before being transferred to and
stored in 70 % ethanol at 4 C for X-ray and histomor-
phometric analyses. The spine was stored at -20 C until
DXA and microCT analyses were performed. All experi-
mental procedures were approved by the Animal Care and
Use Committee at Oklahoma State University.
Whole-Body and Vertebral DXA Absorptiometry
Analyses
Whole-body and vertebral DXA scans were performed to
assess bone mineral content (BMC), bone mineral area
(BMA), and bone mineral density (BMD). Whole-body scans
were completed on anesthetized animals before necropsy.
DXA analyses of the spine were completed by scanning the
excised spine and analyzing the fourth lumbar vertebra.
Biochemical Markers of Bone Metabolism
Systemic markers of bone formation and bone resorption
were analyzed. Serum procollagen type 1 amino-terminal
propeptide (P1NP), which is released from procollagen
during collagen synthesis and is considered an indicator of
bone formation, was assessed using a commercially
available ELISA kit (IDS, Scottsdale, AZ). The sensitivity
of the assay is 0.7 ng/ml, and the inter- and intra-assay
variability was 9.2 and 6.4 %, respectively. In addition,
serum levels of pyridinoline, a bone resorption marker
released during the breakdown of hydroxy lysyl crosslinks
in collagen, were also assessed using an ELISA kit (My-
BioSource, San Diego, CA, USA). The sensitivity of the
assay is\2 pg/ml, and the inter- and intra-assay variability
was \10 and \8 %, respectively.
Glutathione Peroxidase Activity in Serum
Glutathione peroxidase activity, an indicator of antioxidant
capacity, was measured in the serum using a commercially
available assay kit and following the manufacturer’s
guidelines (Cayman Chemical Company, Ann Arbor, MI,
USA). The sensitivity of this dynamic, multimeasurement
assay was 50–344 nmol/min/ml, which represents an
absorbance decrease of 0.02–0.135 per minute. The inter-
and intra-assay variability was 7.2 and 5.7 %, respectively.
Trabecular and Cortical Bone Microarchitecture
MicroCT scans (SCANCO Medical AG, Switzerland) were
performed on the fourth lumbar vertebra and the distal
femoral metaphysis to assess the microstructure of the
trabecular and cortical compartments of bone. A region
(1.8 mm) within the distal femoral metaphysis was scanned
at a resolution of 2,048 9 2,048 pixels, and the volume of
interest (VOI = 0.9 mm) was analyzed by placing semi-
automatic contours to evaluate the secondary spongiosa.
For analysis of vertebral trabecular bone, the lumbar ver-
tebral body was scanned at a resolution of 1,024 9 1,024
pixels. Secondary spongiosa within an *4.2 mm VOI
located between cranial and caudal growth plates was
analyzed. At both sites, trabecular microarchitecture was
analyzed, including trabecular bone volume expressed as a
percentage of total volume (BV/TV), trabecular number
(TbN), trabecular thickness (TbTh), trabecular separation,
connectivity, and the structural model index.
MicroCT scans were also performed on the mid-diaph-
ysis of the femur for cortical bone analyses. An *0.3-mm
region at the midshaft was scanned and analyzed for cor-
tical parameters. Cortical thickness, cortical area, and
porosity as well as medullary area were determined within
the VOI.
Static and Dynamic Bone Histomorphometry
Bone histomorphometry was performed in the secondary
spongiosa within the distal femur metaphysis. Calcein
(10 mg/kg, pH 7.4) was injected 7 and 2 days before the
end of the study to allow for the determination of dynamic
bone histomorphometric indices. Excised femurs were
fixed in 10 % phosphate-buffered formalin, dehydrated in
graded ethanol solutions and xylene, and then embedded
(undecalcified) in methyl methacrylate. Von Kossa staining
with a tetrachrome counterstain was utilized for measure-
ment of osteoblast and osteoclast surfaces in longitudinal
sections (4 lm thick) of the distal femoral metaphysis.
Unstained 8-lm-thick longitudinal sections were used to
determine dynamic indices of cancellous bone formation,
including mineralizing surface (MS/BS), mineral apposi-
tion rate (MAR), and surface-based bone formation rate
(BFR/BS). All measurements were made with the Osteo-
Measure System (Osteometrics, Atlanta, GA, USA).
Gene Expression Analysis in Bone Marrow and Flushed
Femur Using Real-time PCR
Total RNA was extracted from the bone marrow and the
flushed femur specimens using Trizol reagent (Invitrogen,
Rockville, MD, USA) and the protocol provided by the
manufacturer. Briefly, bone marrow samples from the flu-
shed femur were centrifuged at 2,0009g for 5 min, the
supernatant was decanted and RNA extraction with Trizol
was performed. The flushed femur was milled in a liquid
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nitrogen–containing freezer mill (Spex 6770 Freezer Mill)
before RNA extraction using Trizol. The concentration and
quality of the RNA were determined by measuring OD at
260 and 280 nm with a Nanodrop Spectrophotometer
(Rockland, DE, USA) and electrophoretic analysis on an
agarose gel. Total RNA (2 lg) was then pretreated with
DNase I and subjected to reverse transcription (Superscript
II, Invitrogen, Carlsbad, CA, USA). cDNA (50 ng) was
used for each qRT-PCR reaction, and reactions were
evaluated in duplicate using SYBR green chemistry
(Roche, Penzberg, Germany) on Applied Biosystems
7900HT Fast Real-Time PCR System (Foster City, CA,
USA). Gene-specific primers related to osteoblast and
osteoclast differentiation and activity were used to amplify
sequences of interest (Table 1) to determine relative
abundance. Expression levels of each gene were normal-
ized to the reference gene Cyclo in both the bone marrow
and the flushed femur samples. Comparison of the quan-
tification cycle (Cq) was done to determine differences in
gene expression between dietary treatment groups at each
time point.
Statistical Analyses
Statistical analyses were performed by SAS version 9.2
(SAS, Cary, NC, USA). Analysis of treatment effects at
each time point were conducted by Student’s t tests, with
p \ 0.05 considered statistically significant. Data are pre-
sented as means ± standard errors (SE) with n = 5–10
mice/group.
Results
Body Weights, Body Composition, and Food Intake
The mice in both treatment groups continued to experience
an increase in body weight throughout the study, and no
differences occurred in food intake (Table 2). Body mass
did not differ between treatment groups at 4 weeks, but by
the 12-week time point, the DP group had a lower body
mass than the controls (p \ 0.05). On the basis of analysis
of body composition, the DP group had a significantly
lower fat mass compared to the control group, but no dif-
ferences were detected in lean mass (Table 2).
Whole-Body and Vertebral DXA Analyses
Whole-body and vertebral BMD were significantly greater
in the DP group compared to the control group at both 4
and 12 weeks (Table 2). The higher BMD with DP treat-
ment coincided with a significantly greater BMC of the
vertebra (p \ 0.05) at 4 weeks and in both the vertebra and
whole body at 12 weeks. Whole-body BMA was higher
(p \ 0.05) in the DP group at 12 weeks.
Trabecular and Cortical Bone Microarchitectural
Properties
To examine the effect of DP supplementation on the cor-
tical and trabecular components of bone, microCT analyses
were completed on both the fourth lumbar vertebra and the
femur. Similar to the positive effects observed on BMD,
microarchitectural analyses of vertebral trabecular bone
indicated a positive effect of DP as early as 4 weeks, as
BV/TV was greater in the DP group compared to control
(p \ 0.05), but there were no statistically significant dif-
ferences in TbN or TbTh (Table 3). The response of the
trabecular bone in the lumbar vertebra was more rapid than
the distal femur metaphysis as there were no differences
between treatment groups at 4 weeks in any of the tra-
becular parameters in the femur (Table 3). After 12 weeks
of treatment, the DP group had greater BV/TV at both the
vertebral and the distal femoral sites. The alterations in the
trabecular bone at 12 weeks in response to DP were
characterized by a higher TbN and correspondingly
reduced trabecular separation compared to the control
group. Animals receiving the DP diet showed a trend
(p = 0.06) toward increased TbTh in the distal femoral
Table 1 Primer sequences for qPCR
Transcript Sequence (50–30)
BMP4 F: GCC GAG CCA ACA CTG TGA
R: TGG TCC CTG GGA TGT TCT C
Runx2 F: CGA CAG TCC CAA CTT CCT GT
R: CGG TAA CCA CAG TCC CAT CT
Osterix (Osx) F: GAA GTT CAC CTG CCT GCT CTG T
R: CGT GGG TGC GCT GAT GT
ALP F: GGT ATG GGC GTC TCC ACA GT
R: GCC CGT GTT GTG GTG TAG CT
Col1a1 F: CGT CTG GTT TGG AGA GAG CAT
R: GGT CAG CTG GAT AGC GAC ATC
Ocn F: CTG ACA AAG CCT TCA TGT CCA C
R: GCG CCG GAG TCT GTT CAC TA
RANKL F: TCT GCA GCA TCG CTC TGT TC
R: AGC AGT GAG TGC TGT CTT CTG ATA TT
OPG F: TCC CGA GGA CCA CAA TGA AC
R: TGG GTT GTC CAT TCA ATG ATG T
Nfatc1 F: GCG AAG CCC AAG TCT CTT TCC
R: GTA TGG ACC AGA ATG TGA
Ctsk F: GCA GGA TGT GGG TGT TCA AGT
R: TCC GGA GAC AGA GCA AAG CT
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metaphysis at 12 weeks, but there were no statistically
significant improvements in TbTh in the distal femur or
vertebral body at either time point.
Nonmorphometric analyses of trabecular bone also indi-
cated a positive effect of DP (Table 3). The connectivity of
trabecular bone was greater in the DP group at 4 weeks in the
vertebra and in both the vertebra and femur at 12 weeks
(p \ 0.05). A lower structural model index, which is asso-
ciated with a structure that has improved bone biomechanical
properties, was observed with DP supplementation in the
Table 2 Food intake, body weight and composition, and DXA analyses
Characteristic 4-week CON 4-week DP p-value 12-week CON 12-week DP p-value
Food intake (g/mouse/day) 6.4 ± 0.03 6.4 ± 0.11 0.5394 6.3 ± 0.06 6.3 ± 0.05 0.2349
Body weight (g) 35.7 ± 0.8 35.4 ± 0.8 0.4211 42.4 ± 0.5 38.2 ± 0.7* 0.0003
Lean mass (g) 25.1 ± 0.5 24.9 ± 0.4 0.6951 26.1 ± 0.4 25.1 ± 0.5 0.1183
Fat mass (g) 9.1 ± 0.6 9.2 ± 0.8 0.8971 15.0 ± 0.7 11.4 ± 0.8* 0.0029
Fat (%) 26.4 ± 1.3 26.9 ± 1.7 0.9838 36.4 ± 1.3 31.1 ± 1.7* 0.0240
Whole body
BMA (cm2) 11.077 ± 0.206 11.247 ± 0.223 0.5827 10.094 ± 0.217 11.070 ± 0.324* 0.0300
BMC (mg) 569.1 ± 16.7 605.2 ± 16.0 0.1271 514.5 ± 11.5 595.9 ± 14.1* 0.0006
BMD (mg/cm2) 51.3 ± 0.06 53.9 ± 0.06* 0.0086 50.3 ± 0.9 53.5 ± 0.8* 0.0174
Vertebra
BMA (cm2) 1.027 ± 0.019 1.024 ± 0.017 0.9515 1.130 ± 0.03 1.108 ± 0.025 0.5292
BMC (mg) 46.2 ± 0.9 50.6 ± 1.4* 0.0227 50.5 ± 1.2 55.9 ± 1.7* 0.0175
BMD (mg/cm2) 45.2 ± 0.4 49.4 ± 1.1* 0.0029 44.7 ± 0.8 50.5 ± 0.9* 0.0002
DXA dual-energy X-ray absorptiometry, CON control, DP dried plum, BMD bone mineral density, BMC bone mineral content, BMA bone
mineral area
* Treatment group statistically different from control at given time point, p \ 0.05; n = 9–10 mice/group
Table 3 MicroCT analyses of trabecular and cortical bone microarchitecture
Site 4-wk CON 4-wk DP p-value 12-wk CON 12-wk DP p-value
Lumbar vertebra
BV/TV (%) 14.1 ± 0.01 17.6 ± 0.01* 0.0185 13.7 ± 0.01 18.2 ± 0.01* 0.0198
Trabecular number (1/mm2) 4.20 ± 0.10 4.44 ± 0.09 0.1039 4.00 ± 0.14 4.50 ± 0.12* 0.0138
Trabecular thickness (lm) 47.8 ± 0.9 49.2 ± 1.2 0.3717 47.9 ± 1.0 47.9 ± 1.2 1.000
Trabecular separation (lm) 232.5 ± 6.3 218.4 ± 5.7 0.1130 245.0 ± 10.0 214.3 ± 6.7* 0.0194
Conn Dens (1/mm3) 89.4 ± 7.3 117.2 ± 8.6* 0.0260 78.5 ± 9.7 136.7 ± 10.9* 0.0009
SMI 2.03 ± 0.08 1.59 ± 0.13* 0.0122 2.02 ± 0.12 1.50 ± 0.13* 0.0109
Distal femur metaphysis
BV/TV (%) 9.9 ± 0.6 11.6 ± 1.1 0.1827 6.7 ± 0.5 11.0 ± 0.7* 0.0003
Trabecular number (1/mm2) 3.48 ± 0.14 3.71 ± 0.05 0.1421 2.01 ± 0.12 3.02 ± 0.21* 0.0007
Trabecular thickness (lm) 44.6 ± 1.9 46.8 ± 2.7 0.5349 33.3 ± 1.1 37.2 ± 1.8 0.0602
Trabecular separation (lm) 279.7 ± 12.5 256.3 ± 4.4 0.0963 482.5 ± 33.8 307.7 ± 23.1* 0.0025
Conn Dens (1/mm3) 80.4 ± 10.5 84.3 ± 5.0 0.7427 37.5 ± 4.9 66.8 ± 7.5* 0.0105
SMI 1.82 ± 0.10 1.87 ± 0.10 0.7580 2.51 ± 0.06 1.91 ± 0.06* \0.0001
Femur mid-diaphysis
Cortical thickness (mm) 0.201 ± 0.003 0.211 ± 0.002* 0.0267 0.190 ± 0.004 0.213 ± 0.003 0.0026
Cortical area (mm2) 0.997 ± 0.014 1.042 ± 0.014 0.5051 0.949 ± 0.020 1.042 ± 0.014 0.0044
Medullary area (lm2) 10.13 ± 0.32 10.10 ± 0.40 0.9880 11.56 ± 0.35 12.13 ± 0.82 0.5328
Porosity (%) 0.98 ± 0.035 1.00 ± 0.036 0.7575 1.23 ± 0.057 1.109 ± 0.034 0.7599
CON control, DP dried plum, BV/TV trabecular bone volume, Conn Dens connectivity density, SMI structural model index
* Treatment group statistically different from control at given time point, p \ 0.05; n = 9–10 mice/group
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vertebral body at 4 and 12 weeks and in the femur at
12 weeks. These findings indicate that in the DP-treated
animals, the trabeculae had a more platelike structural
arrangement (Table 3).
Cortical bone analyses of the mid-diaphysis of the femur
showed a significantly greater cortical thickness in the DP
group compared to control at both the 4- and 12-week time
points (Table 3). There were no differences between
treatment groups in cortical area, medullary area, or
porosity at 4 weeks, but cortical area was increased
(p \ 0.01) with DP by the 12th week.
Biochemical Markers of Bone Metabolism
Despite an increase in whole-body BMD observed, sys-
temic markers of bone metabolism indicated a suppression
of bone formation at 4 weeks in the DP group. Serum
P1NP was reduced by 43 % in the DP group compared to
control at this time point (Fig. 1a). Interestingly, P1NP
remained suppressed compared to the controls at 12 weeks
(p \ 0.05), but it was apparent that the control P1NP was
*50 % lower than at 4 weeks. There was no difference in
serum pyridinoline between the DP and control groups at
4 weeks, but serum pyridinoline was significantly lower in
the DP group at 12 weeks, indicating a decrease in bone
resorption (Fig. 1b).
Glutathione Peroxidase Activity in Serum
To determine whether the skeletal improvements in the DP
group were linked to greater antioxidant capacity, gluta-
thione peroxidase activity in the serum was examined.
Glutathione peroxidase activity was not different between
groups at 4 weeks (Fig. 2). However, the DP group had
significantly higher glutathione peroxidase activity than the
control at 12 weeks, suggesting a greater antioxidant
capacity as a result of DP supplementation (p \ 0.01).
Bone Histomorphometry
At the end of 4 weeks, the osteoclast (p \ 0.05) and osteo-
blast (p \ 0.001) surfaces of the distal femur metaphysis
were decreased in the DP group compared to control. The
magnitude of this effect was a 62 % reduction in the osteo-
clast surface (Fig. 3a) and a 68 % reduction in the osteoblast
surface (Fig. 3b). Dynamic histomorphometry showed a
suppression of MS/BS (p \ 0.01) (Fig. 3c) and BFR/BS
(p \ 0.05) (Fig. 3d) after 4 weeks of DP supplementation.
Interestingly, after 12 weeks of DP supplementation, can-
cellous BFR/BS and MS/BS rebounded, with the DP group
trending toward statistically greater BFR/BS (p = 0.08) and
MSBS (p = 0.08) than the control group. Both osteoclast
and osteoblast surfaces in the DP group had normalized to the
level of the control group by 12 weeks. MAR was not dif-
















































bFig. 1 DP supplementation
alters serum markers of bone
metabolism at 4 and 12 weeks:
a procollagen type 1 amino
terminal propeptide (P1NP) and
b pyridinoline crosslinks. Bars
represent the mean ± SE. t tests
were performed at each time
point to compare DP treatment
groups to their respective





































Fig. 2 Alterations in serum glutathione peroxidase activity in
response to 4 and 12 weeks of DP treatment. Bars represent the
mean ± SE; t tests were performed at each time point to compare DP
treatment groups to their respective controls. *p \ 0.05; n = 9–10
mice/group
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Gene Expression Markers of Osteoblast and Osteoclast
Differentiation and Activity
Analysis of qRT-PCR data also indicated that osteoblast
differentiation was suppressed at 4 weeks in the DP group
(Fig. 4). The relative abundance of peroxisome prolifera-
tor-activated receptor gamma (Pparc), a nuclear receptor
that regulates the differentiation of mesenchymal stem cells
to the adipocyte versus osteoblast lineage [16], was sig-
nificantly elevated (p = 0.001) in the DP group at 4 weeks
(Fig. 4a). Runt-related transcription factor 2 (Runx2), a
transcription factor necessary for the development of
immature osteoblasts from mesenchymal progenitor cells
[17], tended to be lower (p = 0.08) in the DP group at
4 weeks compared to control (Fig. 4b). Additionally, rel-
ative abundance of osterix (Osx, p \ 0.001), a downstream
target of Runx2 [17], was significantly lower after 4 weeks
of DP supplementation compared to control (Fig. 4c). Bone
morphogenetic protein 2 (Bmp2), an activator of Runx2
[18], tended to be decreased (p = 0.07; Fig. 4d) and Bmp4,
which plays a regulatory role in chondrogenesis [19] and a
potential precursor to future bone formation [20], was
significantly decreased (p = 0.02) (Fig. 4e). There were no
differences in gene expression of these osteoblast differ-
entiation markers between treatment groups at 12 weeks.
Suppression of genes associated with osteoblast activity
at 4 weeks in the DP group was also observed. Alkaline
phosphatase (Alp) (p = 0.01) which is considered an early
marker of osteoblast activity [21] and the extracellular
matrix proteins, collagen type 1, alpha 1 (Col1a1) and
osteocalcin (Bglap2), were significantly reduced (p \ 0.01)
in the DP group compared to control at 4 weeks (Fig. 4f–
h). However, no differences in Alp, Col1a1, and Bglap2
were observed between the DP and control groups after
12 weeks of treatment.
Osteoclast differentiation and activity were also affected
by DP supplementation. Expression of receptor activator of
NF-jB ligand (Rankl) was suppressed in the DP group,
suggesting a decrease in osteoclast differentiation (Fig. 5a).
In contrast, nuclear factor of activated T cells (Nfatc1),
which is a considered a major regulator of RANKL-
induced osteoclast differentiation [22], was up-regulated at
4 weeks in the DP group compared to control (Fig. 5c).
Although this response was not anticipated, it could rep-
resent an attempt to compensate for the decrease in
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Fig. 3 Effects of DP treatment
at 4 and 12 weeks on trabecular
bone histomorphometric indices
of the distal femoral
metaphysis: a osteoclast
surface, b osteoblast surface,
c mineralizing surface, d bone
formation rate, and e mineral
apposition rate. Values
presented are mean ± SE, and
statistical analyses consisted of
t tests to compare treatment
groups at each time point. *DP
treatment group is different
from control at given time point,
p \ 0.05; n = 5–10 mice/group
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role in osteoblast differentiation. As an indicator of
osteoclast activity, the relative expression of cathepsin K
(Ctsk), a protease essential to matrix solubilization found
abundantly in osteoclasts [23], was not different between
treatment groups at either time point (Fig. 5d).
Discussion
Previously, we have reported that 24 weeks of dietary
supplementation with DP resulted in a substantial increase
(i.e., 30–40 %) in trabecular bone mass in aging animals
[15]. These positive effects on bone occurred primarily
during the first 12 weeks of supplementation with DP at
25 % of the diet (w/w). The current study was designed to
investigate the early bone metabolic changes occurring in
response to DP in a model of age-related osteoporosis. The
findings of this study demonstrated for the first time that
the improved bone mass and microarchitecture were con-
sequence of an initial suppression of bone turnover at
4 weeks, followed by normalization of bone remodeling at
least at some anatomical sites after 12 weeks. In the distal
femur metaphysis, osteoblast and osteoclast surfaces were
decreased at the initial time point. These changes coincided
with a reduction in the bone formation rate and mineral-
izing surface in the distal femur and a decrease in plasma
P1NP, a systemic indicator of bone formation. Interest-
ingly, improvements in bone density (whole body and
spine) as well as trabecular bone volume and cortical
thickness occurred at some sites by the end of 4 weeks
despite these metabolic changes. Although the possibility






























































































































































































Fig. 4 Alterations in gene expression related to osteoblast differen-
tiation and activity. The relative mRNA abundance of a peroxisome
proliferator-activated receptor gamma (Pparc), b runt-related tran-
scription factor 2 (Runx2), c osterix (Osx), d bone morphogenetic
protein 2 (Bmp2), e bone morphogenetic protein 4 (Bmp4), f alkaline
phosphatase (Alp), g collagen type 1, alpha 1 (Col1a1), and
h osteocalcin (Bglap2) are shown after 4 and 12 weeks of DP
supplementation. *DP treatment group is different from control at
given time point, p \ 0.05; n = 5–6 mice/group
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resorption that resulted in these improvements in trabecular
and cortical bone cannot be ruled out, these data could
suggest that the metabolic response to DP is similar to that
observed with antiresorptive therapies. Increases in BMD
have been reported with bisphosphonates that dispropor-
tionately suppress the activity of osteoclasts over that of
osteoblasts [24]. It is not clear if this was the case with DP
because of the sizable (i.e., 80 %) decrease in the rate of
bone formation and the inability to directly measure the
rate of bone resorption using histomorphometry [25].
By the end of 12 weeks, DP supplementation had a very
different effect on bone metabolism than the response
observed at the earlier time point. The osteoblast and
osteoclast surfaces of the DP supplemented animals had
normalized to the level of the controls within the cancel-
lous bone of the distal femur. Interestingly, the bone for-
mation rate and mineralization surface increased by 54 and
69 %, respectively, in the DP groups compared to the
controls, but these changes did not reach the level of sta-
tistical significance. Inherent variability in double labeling
for histomorphometric analyses may have contributed to
this lack of a statistically significant response [26]. These
data can lead one to conclude that a biphasic response
occurred in the distal femur metaphysis characterized by an
initial suppression of bone turnover followed by normali-
zation or perhaps even an increase in the activity of the
existing osteoblast on the surface of the cancellous bone.
Hooshmand et al. [14] reported transient changes in bone
metabolism in postmenopausal women consuming DP
(100 g/day) over a 1-year period. They also concluded that
DP inhibited postmenopausal bone loss by suppressing the
accelerated rate of bone turnover associated with ovarian
hormone deficiency [14]. In contrast to the rate of bone
turnover associated with ovarian hormone deficiency, age-
related bone loss results from a decline in the rate of bone
turnover [5]. However, in this study, the serum indicators
of bone formation and resorption (i.e., P1NP and PYD)
continued to be suppressed at 12 weeks despite the fact that
osteoblast and osteoclast surfaces had normalized. When
these systemic biomarkers of bone metabolism are con-
sidered in conjunction with the histomorphometry data at
the distal femoral metaphysis, they suggest that a site-
specific response to DP over time could contribute to the
discrepancy between the histomorphometric data focused
on the distal femur metaphysis and the systemic markers.
Analysis of gene expression provided insight into DPs
effect on transcriptional regulation of osteoblasts differ-
entiation and activity. Early regulators of mesenchymal
cell allocation to the osteoblast lineage include BMP2 and
BMP4, which are members of the transforming growth
factor b superfamily of proteins. These BMPs were origi-
nally identified as requirements for embryonic skeletal
development, but were later recognized for playing a crit-
ical role in osteoblast differentiation and bone formation in
adult bone [27]. Our findings demonstrated that Bmp4 was
significantly suppressed in response to DP compared to
animals on the control diet. BMP2 and BMP4 have been









































































































Fig. 5 Alterations in gene
expression related to osteoclast
differentiation and activity. The
relative mRNA abundance of
a receptor activator of NF-jB
ligand (Rankl) and
b osteoprotegerin (Opg) in the
flushed femur, and c nuclear
factor of activated T cells
(Nfatc1), and d cathepsin K
(Ctsk) in the bone marrow are
shown after 4 and 12 weeks of
DP supplementation. *DP
treatment group is different
from control at given time point,
p \ 0.05; n = 9–10 mice/group
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and its downstream target, Osterix [27, 28]. Although the
relative abundance of Bmp2 and Runx2 in bone was not
altered significantly with DP in this study, the reduction in
osteoblasts coincided with the down-regulation of Osx. Osx
encodes for the transcription factor, Osterix, which is
required for osteoblast formation [28]. Coincident with the
down-regulation of these key mediators of osteoblasto-
genesis, the relative expression of PPARc was increased
([1.6-fold). PPARc is known to direct pluripotent mes-
enchymal stem cells toward the adipocyte lineage as
opposed to osteoblasts or other cells types [16]. Thus, it is
conceivable that the bioactive components in DP are
driving key regulators of osteoblast and adipocyte cell
lineage at 4 weeks away from the osteoblast lineage. In
contrast to the initial inhibition of osteoblast differentiation
and activity that occurred in this study, by the end of 12th
week of DP treatment, the osteoblast surface had returned
to the level of the control animals and there were no sig-
nificant differences in the BMPs Runx2 or Osx at the
transcriptional level.
In conjunction with the decrease in osteoblast surface at
the initial time point, suppression of indicators of osteo-
blast activity was also observed using dynamic bone his-
tomorphometry. The relative abundance of Alp, which
encodes for alkaline phosphatase and which is considered
an indicator of osteoblast cellular activity or number, was
suppressed. Likewise, the expression of Col1a1 and Bglap2
was lower in the DP treated animals. These findings would
indicate that type I collagen which provides the major
extracellular protein structure in bone and osteocalcin, a
noncollagenous protein secreted in the later stages of
osteoblast differentiation to facilitate the formation of
hydroxyapatite, would be down-regulated at the early time
point [29]. Taken together, these alterations in genes
encoding for proteins associated with osteoblast activity
are consistent with the observed decrease in osteoblasts and
their potential to secrete protein matrix occurring in the DP
group when compared to controls at 4 weeks. However,
these responses were temporary, and by the 12-week time
point, there was no indication of transcriptional alterations
associated with osteoblast activity.
Factors involved in regulating osteoclastogenesis and
indicators of osteoclast activity were also investigated to
determine the mechanism through which osteoclasts were
decreased in the distal femoral metaphysis after 4 weeks of
DP supplementation. Rankl, a key differentiation factor for
osteoclastogenesis expressed by osteoblasts [30], was
suppressed in the DP group compared to control at
4 weeks, and there was no alteration in Opg expression.
These findings are in line with our previous report [10]
demonstrating DP suppressed bone resorption by down-
regulating gene expression and proteins levels of RANKL
in bone of gonadal hormone-deficient male rats. However,
in the current study, the relative abundance of Nfatc1 was
unexpectedly increased at 4 weeks in the DP group com-
pared to the control group. We have previously shown in
rodent models of ovarian hormone deficiency that DP
down-regulated Nfatc1 [12]. Whether or not this was
indicative of a compensatory response to the reduction in
osteoclasts is unclear. A contributing factor may have been
the alterations in BMP4. Aside from its role in osteogen-
esis, BMP4 is also considered a regulator of hematopoietic
stem cell, HSC [i.e., c-kit?, Sca-1?, Lin- (KSL) cells],
function and number [31]. However, further studies are
warranted to determine whether a disturbance in the HSC
population induced by DP over the first 4 weeks contrib-
uted to the phenomenon. With regard to osteoclast activity,
no changes in the relative levels of Ctsk were demonstrated
at 4 or 12 weeks. Similar to the observation with osteo-
blasts, by the 12th week of the study, all of the regulators of
osteoclastogenesis were restored to the level of control
animals, which is consistent with the osteoclast surface
histomorphometry data.
Other functional foods that are rich in phenolic com-
pounds have been shown to have bone protective properties
[32–35]. Soy protein and its isoflavones have been one of
the most studied functional foods in relation to bone health.
Soy prevents bone loss in young growing animals and
animal models of gonadal hormone deficiency by sup-
pressing bone resorption and inducing a modest increase in
genes associated with osteoblast differentiation [32, 36,
37]. Other botanical products such as blueberries and green
tea polyphenols have also been shown to protect against
bone loss in animal models of osteoporosis [33–35, 38].
Many of these plant-based foods are known to have bio-
active components with potent antioxidant properties [33,
37–39]. In the current study, we demonstrated that by
12 weeks, DP had increased circulating glutathione per-
oxidase. DP is known to have a high oxygen radical
absorbance capacity score, attributed in large part to it
phenolic compounds [40]. Reactive oxygen species are
known to have negative effects on bone metabolism by
down-regulating osteoblast activity and up-regulating
osteoclast activity [41]. Antioxidants, such as glutathione
peroxidase, are produced by a number of cells, including
osteoblasts [42]. It remains to be determined if the increase
in glutathione peroxidase observed in this study is involved
in mediating the secondary response occurring at 12 weeks
that results in improved bone mass.
The results of these studies show that the osteoprotective
effects of DP in an animal model of age-related bone loss
are associated with an initial suppression of bone turnover
followed by a secondary metabolic phase that may favor
enhanced bone formation. This secondary response to DP
coincided with an increase in systemic glutathione perox-
idase, suggesting that the effects of DP may be mediated
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through antioxidant mechanisms. In agreement with our
previous reports [9–11], we expected that osteoclast
activity would be suppressed; however, the suppression of
osteoblast activity at the early time point was not antici-
pated. To our knowledge, this study is the first to examine
the short-term bone metabolic response to DP in an aging
model and provides new insights into the mechanisms
through which bone is altered. Further studies are needed to
determine the role of glutathione peroxidase in the sec-
ondary metabolic phase induced by DP and the bioactive
components of DP that are exerting these osteoprotective
effects.
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